The Wire · Case news
Court rulings, settlements, and case developments, with links to the source records.
GLP-1 drugs, sight loss and possible claims
A Harvard Medical School team publishes a study in JAMA Ophthalmology reporting that patients prescribed semaglutide had a substantially higher risk of NAION — a hazard ratio of 4.28 among people with type 2 diabetes and 7.64 among overweight or obese patients. The authors note the study is observational and call for further research.
Source: pubmed.ncbi.nlm.nih.gov
GLP-1 drugs, sight loss and possible claims
The U.S. Judicial Panel on Multidistrict Litigation creates In re GLP-1 RAs NAION Products Liability Litigation, MDL No. 3163, in the Eastern District of Pennsylvania before Judge Karen Marston, keeping the vision-loss claims separate from an earlier GLP-1 gastrointestinal-injury litigation.
Source: jpml.uscourts.gov
EtO Exposure and Cancer Claims
The U.S. Environmental Protection Agency recorded enforcement case 06-2025-0910 against Denka Performance Elastomer, listing a federal penalty of $996,703. The action was detected on July 8, 2026, according to EPA's ECHO enforcement database. No additional details about the specific law cited or filing date were included in the available record.
Source: echo.epa.gov
EtO Exposure and Cancer Claims
The EPA recorded a federal penalty of $996,703 against Denka Performance Elastomer in enforcement case 06-2025-0910, according to the EPA ECHO database. The action was detected on July 12, 2026. No additional case details, such as the specific law cited or filing date, were listed in the available record.
Source: echo.epa.gov
Truck crash claim: what can I do?
Between March and May 2026, NHTSA opened at least six separate investigations into truck safety concerns. The probes cover issues including front steering knuckle fractures, rear toe link separation, ABS warning lights, fuel smell with power loss, all-wheel-drive problems, and wheel fastener locking mechanisms. All six investigations were detected by regulatory monitoring on July 9, 2026.
Source: nhtsa.gov
Truck crash claim: what can I do?
Between March and May 2026, NHTSA opened at least five separate investigations into truck-related safety concerns. The probes cover front steering knuckle fractures, rear toe link separation, loss of power steering assist, wheel fastener locking mechanisms, and an all-wheel-drive allegation. No recalls or enforcement actions have been announced based on the available signals.
Source: nhtsa.gov
Baby food, metals and possible claims
On June 25, 2026, the U.S. Consumer Product Safety Commission announced that Shield Line was recalling MedPride Baby Oil bottles because the packaging does not meet mandatory child-resistant standards, creating a risk of serious injury or death from child poisoning. The product is sold in a clear bottle with a pink cap and white-and-pink labeling bearing the MedPride logo. This recall (CPSC Recall #26577) was issued under mandatory child-resistant packaging requirements.
Source: cpsc.gov
Baby food, metals and possible claims
On June 25, 2026, the U.S. Consumer Product Safety Commission issued Recall No. 26577 for MedPride Baby Oil bottles, citing a risk of serious injury or death from child poisoning. According to the CPSC, the bottles violate the mandatory standard for child-resistant packaging. The product comes in a clear bottle with a pink cap and white-and-pink labeling bearing the MedPride logo.
Source: cpsc.gov
Bard PowerPort claims: who can file and what to do
The FDA classified multiple Arrow International, LLC vascular access kits — including PICC, hemodialysis, and CVC kits — under Class I recalls after Lidocaine, Bupivacaine, and 0.9% sodium chloride from a supplier with documented quality issues were incorporated into the products. The FDA noted limited reports of drug ineffectiveness and warned that compromised sterility of a water-based injectable product could lead to serious adverse health consequences. These recalls were detected on June 30, 2026.
Source: api.fda.gov
Bard PowerPort claims: who can file and what to do
The FDA issued a Class I recall against Arrow International, LLC after kits and sets were found to contain drugs — including Lidocaine, Bupivacaine, and 0.9% sodium chloride — sourced from a supplier with identified quality issues. The agency noted limited reports of drug ineffectiveness and warned that compromised sterility in a water-based injectable product could lead to serious health consequences. This recall was detected on June 30, 2026.
Source: api.fda.gov
Birth Injury: What Families Can Check
On July 2, 2026, the U.S. Consumer Product Safety Commission issued two separate recalls affecting infant sleep and feeding products. VEVOR baby loungers were recalled due to entrapment and fall hazards and for violating mandatory infant sleep product standards. AMASKY nursing pillows, sold on Amazon by Pretty-Life, were recalled due to suffocation risk and for violating mandatory standards for nursing pillows and infant support cushions.
Source: cpsc.gov
Birth Injury: What Families Can Check
On July 2, 2026, the U.S. Consumer Product Safety Commission issued Recall No. 26-591 for VEVOR baby loungers, citing risks of serious injury or death from entrapment and fall hazards. The CPSC stated the products violate the mandatory federal standard for infant sleep products. Recalled units were sold in multiple colors and prints, including snow deer, good night, forest friends (oval), forest friends (backpack), and green.
Source: cpsc.gov